Published data by Decibel’s founders suggest that by restoring the synapse, the inner ear hearing circuit can be preserved, and hearing can be restored and maintained. Emerging data also suggest that synaptopathy is likely more prevalent than currently estimated by traditional audiometric measurements. This “hidden hearing loss” could represent a major source of sound fidelity and speech recognition deficits across multiple populations, and may precede a progressive decline in hearing. Decibel’s unique capabilities encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics, and target identification. This comprehensive discovery and development platform enables Decibel Therapeutics to identify, develop and deliver novel hearing loss therapies to targeted populations with different forms of hearing disorders.